Recent clinical evidence supports intranasal insulin administration also in memory-impaired patients such as those with mild cognitive impairment (MCI), AD, Parkinson’s disease (PD), and multiple system atrophy diagnosis [37,38,39,40,41,42,43]. This evidence concerns the gene INS and Parkinson disease.